A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion
Construction of a 3D Multicellular Bioprinted Human Colorectal Cancer Immune-Stromal Microenvironment Model and Its Clinical Translational Research
Colorectal cancer (CRC) has shifted toward a patient-personalized precision medicine paradigm; however, the high heterogeneity and complex tumor microenvironment (TME) of CRC restrict the development of individualized therapy, and existing preclinical models and multi-omics technologies are insufficient to broadly benefit patients. Building on previous research, this project intends to use 3D multicellular bioprinting (3DMP) to incorporate key TME components-cancer-associated fibroblasts (CAFs) and PBMC immune cells-to construct patient-derived CRC-CAFs/PBMC 3DMP models, aiming to apply them to personalized clinical drug screening and prognosis prediction, and to combine them with multi-omics technologies to advance preclinical research on CRC. The implementation of this study will help address the bottleneck of the lack of broadly applicable preclinical models for advancing CRC precision therapy. It has major clinical translational value, will bring significant changes to CRC preclinical research platforms, and will help promote the development of cancer precision medicine.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Yilei Mao, MD PHD
- Telefonnummer: 8600-010-69156042
- E-post: pumch-liver@hotmail.com
Studieorter
-
-
Zhejiang
-
Ningbo, Zhejiang, Kina
- Rekrytering
- Ningbo Medical Center Lihuili Hospital
-
Kontakt:
- Zhou Bo
- Telefonnummer: 8600-0574-87018701
- E-post: 1955729746@qq.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Clinically and pathologically proven colorectal cancer patients are considered as potential candidates of this study. Medical history will be thouroughly taken by clincal practicitioners. Only patients older than 18 years will be included. Those with medical hostory of other malignancies or serious diseases will be excluded. Patients who are not able to sign the informed consent independently will not be included in this study. All the patients included in this study will receive adjuvant/neoadjuvant chemotherapy and surgical resection for the treatment of CRC.
Beskrivning
Inclusion Criteria:
- More than 18 years old
- Diagnosed as colorectal cancer with or without liver metastases before
- Pathologically proven colorectal cancer after surgery
Exclusion Criteria:
- Medical history with other malignancies or serious diseases
- Disable to sign the informed consent independently
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Patients with colorectal cancer who underwent surgical resection received adjuvant chemotherapy
Surgical resection will be performed for locoregional lesions. Regimens of adjuvant chemotherapy are directed by clinical guidance and experience. |
Surgical resection will be performed for locoregional lesions. Regimens of adjuvant chemotherapy are directed by clinical guidance and experience. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.
Tidsram: 2025.05-2026.12
|
The investigators will establish and culture 3D colorectal cancer models and organoids. The 3D models and organoids will be treated with the same chemotherapy drugs as the corresponding patients. The viability of the 3D tumor models and organoids will be observed after treatment and the IC50 of each drug will be calculated. The correlation of 3D model/organoid sensitivity and the patient response will be analyzed. |
2025.05-2026.12
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Response of the colorectal cancer patients to adjuvant chemotherapy.
Tidsram: 2025.05-2026.12
|
The response to adjuvant chemotherapy will be evaluated according to PFS. Regular follow-ups will be conducted, and PFS is difined as the interval between the date of surgery and the date of last follow-up or recurrence/progression. |
2025.05-2026.12
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Yilei Mao, MD PHD, Peking Union Medical College Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolonsjukdomar
- Kolorektala neoplasmer
- Terapeutik
- Narkotikabehandling
- Kombinerad modalitetsterapi
- Kemoterapi, adjuvans
Andra studie-ID-nummer
- CRC-CAFs-3DP-Bioprint
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data (IPD) can be accessed with reasonable requests via e-mail. IPD will be shared after the study is completed.
Tidsram för IPD-delning
The IPD data will available after the study is completed.
Kriterier för IPD Sharing Access
Data can be accessed via e-mail with reasonable requests.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .